Hepatic lipogranulomas in patients with chronic liver disease: Association with hepatitis C and fatty liver disease

Table 1 Distribution and incidence of lipogranuloma in 376 sequential liver biopsy specimens n (%)

Disease	Patients1	Lipogranuloma patients	P
HCV (all)	217 (58)	46 (21)	0.0002
HCV alone	160 (43)	36 (22.5)	0.0001
HCV + FLD	38 (10)	7 (18)	0.0200
HCV + other	19 (5)	3 (16)	0.1000
FLD (all)	80 (21)	14 (18)	0.0070
FLD alone	24 (6.4)	5 (21)	0.0240
FLD + HCV	38 (10)	7 (18)	0.0200
FLD + other	18 (5)	2 (11)	0.2600
Non-HCV/FLD	116 (31)	5 (4)
HBV	56 (15)	2 (3.6)
PBC	11 (3)	1 (9)
AIH	13 (3.5)	1 (7.7)
Other	47 (13)	3 (6)

¹Some patients had more than one disease. P: Fisher's exact test, two-tailed value vs non-HCV/FLD. HCV: Hepatitis C virus; FLD: Fatty liver disease; HBV: Hepatitis B virus; PBC: Primary biliary cirrhosis; AIH: Autoimmune hepatitis.

Table 2 Clinical risk factors for fatty liver disease in 15 patients with lipogranuloma

Patient	Diagnosis	Alcohol hx	Diabetesmellitus	Hyper-lipidemia	Obesity
1	Cirrhosis, 4/4	Y	N	N	N
2	HCV, 3/4	N	N	Y	N
3	HBV, 1/4	N	N	Y	N
4	HCV, 2/4	Y	N	N	N
5	HCV, 2/4	Y	N	Y	Y
6	HCV, 1/4	?	N	?	Y
7	HCV, 2/4	Y	N	N	N
8	HCV, 2/4	Y	N	N	N
9	HCV, 1/4, iron 2/4	Y	?	?	N
10	HCV, FLD, 1/4	Y	N	N	N
11	HCV, 1/4	Y	N	N	Y
12	Resolving FLD	N	N	N	Y
13	AIH	N	N	N	Y
14	FLD	N	N	Y	Y
15	HCV, 1/4	N	N	Y	Y
Total	15	8	0	5	7

HCV: Hepatitis C virus; FLD: Fatty liver disease; HBV: Hepatitis B virus; AIH: Autoimmune hepatitis.